Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations.

doi:10.1126/sciadv.adx3505

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations.

Science advances - 12 Sept 2025

Kim Teha, Bimler Lynn, Ronzulli Sydney L, Song Amber Y, Johnson Scott K, Jones Cheryl A, Tompkins S Mark, Paust Silke

Abstract excerpt

Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e). Combined at low dose, this "triple M2e-mAb"...

Read the complete abstract on PubMed

Topics

Animals
Humans
Mice
Antibodies, Viral
Mutation
Viral Matrix Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Influenza A virus

Antibodies, Monoclonal

Antibodies, Neutralizing

Orthomyxoviridae Infections

Epitopes

Influenza, Human

Viroporin Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 40929256
DOI: 10.1126/sciadv.adx3505
PMCID: PMC12422200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations.PMID 40929256Read ↗

A Low-Dose Triple Antibody Cocktail Against the Ectodomain of the Matrix Protein 2 of Influenza A Is A Universally Effective and Viral Escape Mutant Resistant Therapeutic AgentSemantic proximity Read ↗

In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression.Semantic proximity Read ↗

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.Semantic proximity Read ↗

Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A virusesSemantic proximity Read ↗

Therapeutic Potential of SARS-CoV-2-Specific Monoclonal Antibody CR3022Semantic proximity Read ↗

Fc-engineered antibody therapeutics with improved efficacy against COVID-19Semantic proximity Read ↗

Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availabilitySemantic proximity Read ↗

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B virusesSemantic proximity Read ↗

Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escapeSemantic proximity Read ↗

Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase.Semantic proximity Read ↗

Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A virusesSemantic proximity Read ↗

Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.